Venture Firm Avalon Turns To GSK To Share Biotech Risk
This article was originally published in Start Up
Entering its fourth decade, Avalon fights through “dark days” and taps GlaxoSmithKline to help fund its next crop of early-stage start-ups. In exchange, it must deliver assets, not platforms, to trigger a GSK acquisition of those start-ups, with pre-arranged returns.
You may also be interested in...
Avalon-backed RQx will team with Genentech to discover and develop antibiotics against a novel, undisclosed target. The deal essentially is an exit for hybrid VC firm Avalon, which already has exit deals this year with BioMarin and Genentech.
The pharma pledges $50 million to the California firm’s new seventh round, which it anticipates closing more than eight years after its sixth. For GSK, it’s the latest tie-up with a VC firm as part of a regional investment strategy.
Index Life VI is the first life-sciences-only fund for Index; GSK’s Moncef Slaoui and J&J’s Paul Stoffels are on scientific advisory board.